News Archive - Ultimovacs

Biostock article on Ultimovacs’ clinical data presented at ASCO

“This year’s virtual ASCO conference featured Ultimovacs’ recently released phase I data showing that cancer vaccine UV1 boosts the effects […]

See the whole interview here

“Yesterday, Ultimovacs reported the first results from a Phase I trial of UV1 in advanced melanoma in combination with Keytruda. […]

“Det norske selskapet Ultimovacs står bak kreftvaksinen UV1. Over år ha selskapet forsket på vaksinen som er en peptid-basert vaksine, […]

“Ultimovacs UV1 kreftvaksine i kombinasjon med immunterapien Keytruda har effekt på 60 prosent av pasientene med avansert føflekkreft. 60 prosent […]

“It would seem like Ultimovacs is on to something with its cancer vaccine UV1. New data from their phase I […]

List of events where the Ultimovacs team will attend or present.

13 april, 2021 “The American Association for Cancer Research kicked off its annual meeting last week to put the top […]

26 februari, 2021 “After presenting their 2020 Q4 report, Ultimovacs immediately turned their attention back to 2021 by announcing the […]

“2020 was a year of key clinical advancements for Ultimovacs. In particular, the company’s already extensive development program with top […]